Evaluation, in Humans, of the Correlation Between Hepatotoxicity, Neurotoxicity Induced by Oxaliplatin, and Blood Levels of HMGB1

Inclusion criteria

• ECOG WHO Performance status = 0 or 1
• Signed and dated informed consent
• Patients with histological diagnosis of oesogastric or pancreatic adenocarcinoma
• Resectable tumors
• Patients able to have a laparoscopy
• In case of absence of peritoneal invasion on the laparoscopy, patient candidate to a chemotherapy schedule by FLOT or FOLFOX in perioperative setting for oesogastric adenocarcinoma, or FOLFIRINOX in perioperative setting for pancreatic adenocarcinoma
• Registration in a national health care system (CMU included)
• Patient speak and understand the french

Exclusion criteria

• Histology other than adenocarcinoma
• Metastatic disease
• History of previous treatment with oxaliplatine
• History of systemic chemotherapy administration within 5 years prior to inclusion,
• Patient with an non balanced progressive condition/disease (liver failure, renal failure (creatinine clearance <30mL/min), respiratory failure, congestive heart failure, myocardial infarction in the last 6 months, etc.),
• Patient on curative dose anticoagulant,
• Patient with complete dihydropyrimidine dehydrogenase deficiency (Uracilemia ≥ 150 ng/ml),
• Patient not operable for the pathology concerned,
• Pregnant or breastfeeding woman, woman of childbearing age who has not performed a pregnancy test before the procedure,
• Patient with legal incapacity (person deprived of liberty or under curatorship, stutorship, safeguard of justice),
• Patient who, for psychiatric, social, family or geographical reasons, cannot be followed and/or comply with the requirements of the study,,
• Discovery of peritoneal invasion during the peritoneal exploratory of the laparoscopy